Sanofi can’t even buy a break now, as rival Novo speeds ahead on diabetes showdown
Things are just not going Sanofi’s way. Late last week, just a couple of days before Pfizer scooped out Medivation after slamming the French …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
